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Antimicrobial
Resistance in
Campylobacter
To the Editor: We wish to rectify
several errors in our commentary,
Antibiotics in Animal Feed and
Spread of Resistant Campylobacter
from Poultry to Humans (1). The flu-
oroquinolone enrofloxacin was
approved in 1996 for therapeutic use
by addition to drinking water upon the
decision of a licensed veterinarian
“for the control of mortality in chick-
ens associated with Escherichia coli
organisms and control of mortality in
turkeys associated with E. coli and
Pasteurella multocida organisms” (2).
This therapeutic use was withdrawn
(3) but is now under appeal. Initial
approval and subsequent efforts to
withdraw use of enrofloxacin in the
United States parallel the earlier trend
in Europe and specifically Denmark,
where the use of antimicrobial agents
as growth promoters has been banned
(4). 
Enrofloxacin is not approved for
prophylactic or growth promotion use
in poultry feed as stated in our com-
mentary and in the first section of the
flowchart (1). However, when
enrofloxacin is added to the drinking
water of poultry, large numbers of
both ill and healthy animals are
exposed to the agent (5). Although
extra-label use of enrofloxacin is pro-
hibited, microbiologic culture of
either of the cited bacteria is not
required before administration (2).
Despite the restrictions on
enrofloxacin use, emergence of fluo-
roquinolone-resistant Campylobacter
species, with poultry as an important
source, has been documented in the
United States (5,6). Thus the decision
to withdraw therapeutic use of
enrofloxacin (3) was warranted.
Therefore, our conclusion remains:
use of enrofloxacin in poultry materi-
ally contributed to increase in human
infection by fluoroquinolone-resistant
Campylobacter species. Given the
above, our commentary should have
been entitled Use of Antibiotics in the
Poultry Industry and Spread of
Resistant Campylobacter to Humans.
We regret the errors and hope we have
clarified this issue. 
Nicole M. Iovine* 
and Martin J. Blaser*†
*New York University School of Medicine,
New York, New York, USA; †New York
Harbor Department of Veterans Affairs
Medical Center, New York, New York, USA
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